Search results
Novartis Gets FDA Breakthrough Therapy Designation for Scemblix
Morningstar· 8 hours agoNovartis said the U.S. drug regulator decided to expedite the development of Scemblix, to treat adults newly diagnosed with leukemia. The Swiss pharmaceutical company said ...
Novartis AG ADR (NVS) Stock: Analyzing the Market Value – News Heater
NewsHeater· 1 day agoNovartis AG ADR (NYSE: NVS) has a higher price-to-earnings ratio of 13.52x compared to its average ratio, The 36-month beta value for NVS is at 0.58. The average trading volume ...
Benjamin F. Edwards & Company Inc. Has $647,000 Stock Position in Novartis AG (NYSE:NVS)
ETF DAILY NEWS· 3 days agoBenjamin F. Edwards & Company Inc. boosted its holdings in shares of Novartis AG (NYSE:NVS – Free Report) by 6.3% in the fourth quarter, according to its most recent filing ...
Drugmakers in Medicare negotiations spent more on shareholder payments and marketing than R&D last...
The Hill via Yahoo Finance· 2 days agoA new report from the center-left watchdog group Accountable US found that most major drugmakers...
Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into Financials and Strategic Highlights
GuruFocus.com via Yahoo Finance· 2 hours agoThe decrease in revenue was largely attributed to the termination of collaboration agreements with major partners such as Biogen and Novartis in mid-2023, and the expiration ...
Swiss Market Ends On Strong Note
RTT News· 4 hours agoSwiss stocks closed on a buoyant note on Friday, tracking gains in global markets amid optimism several central banks will start cutting interest rates soon..
Drugmakers in Medicare Price Talks Spent Less on R&D Than on Shareholders, Marketing, Overhead:...
The Fiscal Times via Yahoo Finance· 23 hours agoThe report says that the eight companies — Johnson & Johnson, Amgen, AstraZeneca, Bristol Myers...
2 Magnificent Dividend Stocks to Hold for the Next Decade
Motley Fool via Yahoo Finance· 5 days agoThe obvious corollary is, not every dividend payer on the market is worth investing in. But let's...
Intellia Therapeutics Q1 2024 Earnings: Aligns with Analyst Projections Amidst Strategic Advances
GuruFocus.com via Yahoo Finance· 4 hours agoIntellia's strategic collaborations with industry giants like Regeneron and Novartis underscore its significant role in advancing gene therapy. Operational and Clinical Progress ...
Questor: this medical stock is expensive – but worth paying for
The Telegraph via Yahoo Finance· 5 days agoIt’s a stock market rule of thumb that big acquisitions tend to destroy shareholder value....